U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23ClN2O2.ClH
Molecular Weight 419.344
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORATADINE HYDROCHLORIDE

SMILES

Cl.CCOC(=O)N1CCC(CC1)=C2C3=C(CCC4=C2N=CC=C4)C=C(Cl)C=C3

InChI

InChIKey=DUWMKTXPAFUTGI-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2.ClH/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20;/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3;1H

HIDE SMILES / InChI

Description

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLARITIN

Cmax

ValueDoseCo-administeredAnalytePopulation
10.8 ng/mL
20 mg single, oral
LORATADINE plasma
Homo sapiens
27.1 ng/mL
40 mg 1 times / day steady-state, oral
LORATADINE plasma
Homo sapiens
4 ng/mL
5 mg 1 times / day steady-state, oral
DESLORATADINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
34.4 ng × h/mL
20 mg single, oral
LORATADINE plasma
Homo sapiens
96 ng × h/mL
40 mg 1 times / day steady-state, oral
LORATADINE plasma
Homo sapiens
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
DESLORATADINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
20 mg single, oral
LORATADINE plasma
Homo sapiens
14.4 h
40 mg 1 times / day steady-state, oral
LORATADINE plasma
Homo sapiens
27 h
5 mg 1 times / day steady-state, oral
DESLORATADINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
DESLORATADINE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration: Oral
In Vitro Use Guide
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.